Dr. Russell Palm is an Assistant Member in the Department of Radiation Oncology at Moffitt Cancer Center. Dr. Palm received his MD from University of Toledo College of Medicine and most recently completed a Radiation Oncology Residency at Moffitt Cancer Center/University of South Florida. Dr. Palm’s clinical expertise involves use of radiation therapy to treat patients with esophageal, gastric, hepatobiliary, pancreatic, rectal, and anal cancers. Dr. Palm’s research aims include: improving patient selection to safely allow for organ preservation through imaging or biological markers predictive of tumor response, integrating immunotherapy and radiosensitizers in the definitive treatment of gastrointestinal cancers, and optimizing care for patients with oligometastatic disease.
Education & Training
- Moffitt Cancer Center - Radiation Oncology
- University of Toledo - Doctor of Medicine
- Palm RF, Boyer E, Kim DW, Denbo J, Hodul PJ, Malafa M, Fleming JB, Shridhar R, Chuong MD, Mellon EA, Frakes JM, Hoffe SE. Neoadjuvant chemotherapy and stereotactic body radiation therapy for borderline resectable pancreas adenocarcinoma: influence of vascular margin status and type of chemotherapy. HPB (Oxford). 2023 Sep.25(9):1110-1120. Pubmedid: 37286392.
- Liveringhouse CL, Palm RF, Bryant JM, Yang GQ, Mills MN, Figura ND, Ahmed KA, Mullinax J, Gonzalez R, Johnstone PA, Naghavi AO. Neoadjuvant Simultaneous Integrated Boost Radiation Therapy Improves Clinical Outcomes for Retroperitoneal Sarcoma. Int J Radiat Oncol Biol Phys. 2023 Sep.117(1):123-138. Pubmedid: 36935026.
- Sinnamon AJ, Mehta R, Saeed S, Lauwers GY, Palm RF, Frakes JM, Hoffe SE, Baldonado JJ, Fontaine JP, Pimiento JM. Induction Fluorouracil-Based Chemotherapy and PET-Adapted Consolidation Chemoradiation with Esophagectomy for High-Risk Gastroesophageal Adenocarcinoma. Cancers (Basel). 2023 Sep.15(17). Pubmedid: 37686650. Pmcid: PMC10486661.
- Mehta R, Sinnamon A, Dam A, Walko C, Palm R, Barton L, Lauwers G, Pimiento JM. Locally advanced mismatch repair-deficient gastroesophageal junction cancer: Diagnosis, treatment modifications, and monitoring. CA-Cancer J Clin. 2023 Oct. Pubmedid: 37849051.
- Eshmuminov D, Aminjonov B, Palm RF, Malleo G, Schmocker RK, Abdallah R, Yoo C, Shaib WL, Schneider MA, Rangelova E, Choi YJ, Kim H, Rose JB, Patel S, Wilson GC, Maloney S, Timmermann L, Sahora K, Rössler F, Lopez-Lopez V, Boyer E, Maggino L, Malinka T, Park JY, Katz MHG, Prakash L, Ahmad SA, Helton S, Jang JY, Hoffe SE, Salvia R, Taieb J, He J, Clavien PA, Held U, Lehmann K. FOLFIRINOX or Gemcitabine-based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-institutional, Patient-Level, Meta-analysis and Systematic Review. Ann Surg Oncol. 2023 Jul.30(7):4417-4428. Pubmedid: 37020094. Pmcid: PMC10250524.
- Eshmuminov D, Aminjonov B, Palm RF, Lehmann K. ASO Author Reflections: Chemotherapy Regimen in Borderline Resectable and Locally Advanced Pancreatic Cancer-Resection Cuts the Deal. Ann Surg Oncol. 2023 Jul.30(7):4429-4430. Pubmedid: 37074518. Pmcid: PMC10250261.
- Chuong MD, Palm RF, Tjong MC, Hyer DE, Kishan AU. Advances in MRI-Guided Radiation Therapy. Surg Oncol Clin N Am. 2023 Jul.32(3):599-615. Pubmedid: 37182995.
- Eshmuminov D, Aminjonov B, Palm RF, Malleo G, Schmocker RK, Abdallah R, Yoo C, Shaib WL, Schneider MA, Rangelova E, Choi YJ, Kim H, Rose JB, Patel S, Wilson GC, Maloney S, Timmermann L, Sahora K, Rössler F, Lopez-Lopez V, Boyer E, Maggino L, Malinka T, Park JY, Katz MHG, Prakash L, Ahmad SA, Helton S, Jang JY, Hoffe SE, Salvia R, Taieb J, He J, Clavien PA, Held U, Lehmann K. ASO Visual Abstract: FOLFIRINOX or Gemcitabine Based Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Cancer: A Multi-Institutional, Patient-Level Meta-Analysis and Systematic Review. Ann Surg Oncol. 2023 Jul.30(7):4431-4432. Pubmedid: 37067744.
- Bryant JM, Palm RF, Herrera R, Rubens M, Hoffe SE, Kim DW, Kaiser A, Ucar A, Fleming J, De Zarraga F, Hodul P, Aparo S, Asbun H, Malafa M, Jimenez R, Denbo J, Frakes JM, Chuong MD. Multi-Institutional Outcomes of Patients Aged 75 years and Older With Pancreatic Ductal Adenocarcinoma Treated With 5-Fraction Ablative Stereotactic Magnetic Resonance Image-Guided Adaptive Radiation Therapy (A-SMART). Cancer Control. 2023 Jan.30. Pubmedid: 36598464.
- Palm RF, Liveringhouse CL, Gonzalez RJ, Bui MM, Binitie O, Yang GQ, Naghavi AO. Effect of Favorable Pathologic Response After Neoadjuvant Radiation Therapy Alone in Soft-tissue Sarcoma. Adv Radiat Oncol. 2023 Jan.8(1):101086. Pubmedid: 36483058. Pmcid: PMC9723307.
- Bryant JM, Palm RF, Liveringhouse C, Boyer E, Hodul P, Malafa M, Denbo J, Kim D, Carballido E, Fleming JB, Hoffe S, Frakes J. Surgical and Pathologic Outcomes of Pancreatic Adenocarcinoma (PA) After Preoperative Ablative Stereotactic Magnetic Resonance Image Guided Adaptive Radiation Therapy (A-SMART). Adv Radiat Oncol. 2022 Nov.7(6):101045. Pubmedid: 36420193. Pmcid: PMC9677195.
- Sim AJ, Hoffe SE, Latifi K, Palm RF, Feygelman V, Leuthold S, Dookhoo M, Dennett M, Rosenberg SA, Frakes JM. A Practical Workflow for Magnetic Resonance-Guided Stereotactic Body Radiation Therapy to the Pancreas. Pract Radiat Oncol. 2022 Jul.13(1):e45-e53. Pubmedid: 35901947.
- Palm RF, Eicher KG, Sim AJ, Peneguy S, Rosenberg SA, Wasserman S, Johnstone PAS. Assessment of MRI-Linac Economics under the RO-APM. J Clin Med. 2021 Oct.10(20). Pubmedid: 34682829. Pmcid: PMC8539760.
- Cummings D, Wong J, Palm R, Hoffe S, Almhanna K, Vignesh S. Epidemiology, Diagnosis, Staging and Multimodal Therapy of Esophageal and Gastric Tumors. Cancers (Basel). 2021 Feb.13(3). Pubmedid: 33540736. Pmcid: PMC7867245.
- Tomaszewski MR, Latifi K, Boyer E, Palm RF, El Naqa I, Moros EG, Hoffe SE, Rosenberg SA, Frakes JM, Gillies RJ. Delta radiomics analysis of Magnetic Resonance guided radiotherapy imaging data can enable treatment response prediction in pancreatic cancer. Radiat Oncol. 2021 Dec.16(1):237. Pubmedid: 34911546. Pmcid: PMC8672552.
- Sim AJ, Palm RF, DeLozier KB, Feygelman V, Latifi K, Redler G, Washington IR, Wuthrick EJ, Rosenberg SA. MR-guided stereotactic body radiation therapy for intracardiac and pericardial metastases. Clin Transl Radiat Oncol. 2020 Nov.25:102-106. Pubmedid: 33204858. Pmcid: PMC7653008.
- Palm RF, Jim HSL, Boulware D, Johnstone PAS, Naghavi AO. Using the revised Edmonton symptom assessment scale during neoadjuvant radiotherapy for retroperitoneal sarcoma. Clin Transl Radiat Oncol. 2020 May.22:22-28. Pubmedid: 32181374. Pmcid: PMC7063105.
- Palm RF, Hoffe SE. Increasing Incidence and Knowledge Gaps Within a Clinical Challenge: Understanding the Paradox and Complexities of Young-Onset Colorectal Cancer. JCO Oncol Pract. 2020 Jan.16(1):28-29. Pubmedid: 32039663.
- Javadi S, Eckstein J, Ulizio V, Palm R, Reddy K, Pearson D. Evaluation of the use of abdominal compression of the lung in stereotactic radiation therapy. Med Dosim. 2020 Apr.44(4):365-369. Pubmedid: 30852064.
- Palm RF, Oliver DE, Yang GQ, Abuodeh Y, Naghavi AO, Johnstone PAS. The role of dose escalation and proton therapy in perioperative or definitive treatment of chondrosarcoma and chordoma: An analysis of the National Cancer Data Base. Cancer. 2019 Feb.125(4):642-651. Pubmedid: 30644538.
- Blair JA, Palm R, Chang J, McGee H, Zhu X, Wang X, Casadesus G. Luteinizing hormone downregulation but not estrogen replacement improves ovariectomy-associated cognition and spine density loss independently of treatment onset timing. Horm Behav. 2016 Feb.78:60-66. Pubmedid: 26497249. Pmcid: PMC4718885.
- Blair JA, McGee H, Bhatta S, Palm R, Casadesus G. Hypothalamic-pituitary-gonadal axis involvement in learning and memory and Alzheimer's disease: more than "just" estrogen. Front Endocrinol (Lausanne). 2015 Mar.6:45. Pubmedid: 25859241. Pmcid: PMC4373369.
- Palm R, Chang J, Blair J, Garcia-Mesa Y, Lee HG, Castellani RJ, Smith MA, Zhu X, Casadesus G. Down-regulation of serum gonadotropins but not estrogen replacement improves cognition in aged-ovariectomized 3xTg AD female mice. J Neurochem. 2014 Jul.130(1):115-125. Pubmedid: 24601954. Pmcid: PMC4672731.
- Adler BL, Yarchoan M, Hwang HM, Louneva N, Blair JA, Palm R, Smith MA, Lee HG, Arnold SE, Casadesus G. Neuroprotective effects of the amylin analogue pramlintide on Alzheimer's disease pathogenesis and cognition. Neurobiol Aging. 2014 Apr.35(4):793-801. Pubmedid: 24239383.
- Palm R, Ayala-Fontanez N, Garcia Y, Lee HG, Smith MA, Casadesus G. Neuroendocrinology-based therapy for Alzheimer's disease. Biofactors. 2012 Aug.38(2):123-132. Pubmedid: 22438197.
Patient CommentsOverall Satisfaction4.9
90 patients rated this provider
The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.
Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.Learn more about our patient satisfaction survey
Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.
We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.
Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.
Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:
- The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
- He or she may be a researcher or other type of provider that does not see patients.
- The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.